Introduction to the Hematopoietic Growth Factors

Chapter
Part of the Cancer Treatment and Research book series (CTAR, volume 157)

Abstract

The hematopoietic growth factors (HGFs) are an important class of biologic molecules which augment production and functional maturation of hematopoietic cells. As shown in Fig. 1.1, endogenous production of HGFs modulates a wide variety of both hematopoietic and nonhematopoietic cells derived from the myeloid stem cell including progenitor and precursor cells and more functionally mature cells. Clinically, recombinant or mimetic forms of these cytokines are utilized to reduce the severity and duration of hematologic complications resulting from impairment of granulocytopoiesis, erythropoiesis, or thrombopoiesis.

Keywords

Introduction Hematopoietic Growth Factors 

References

  1. 1.
    Metcalf D. Studies on colony formation in vitro by mouse bone marrow cells. I. Continuous cluster formation and relation of clusters to colonies. J Cell Physiol. 1969;74:323–32.CrossRefPubMedGoogle Scholar
  2. 2.
    Metcalf D, Foster R. Bone marrow colony-stimulating activity of serum from mice with viral-induced leukemia. J Natl Cancer Inst. 1967;39:1235–45.PubMedGoogle Scholar
  3. 3.
    Clark SC, Kamen R. The human hematopoietic colony-stimulating factors. Science. 1987;236:1229–37.CrossRefPubMedGoogle Scholar
  4. 4.
    Burgess AW, Metcalf D. Characterization of a serum factor stimulating the differentiation of myelomonocytic leukemic cells. Int J Cancer. 1980;26:647–54.CrossRefPubMedGoogle Scholar
  5. 5.
    Moore MA. G-CSF: its relationship to leukemia differentiation-inducing activity and other hemopoietic regulators. J Cell Physiol Suppl. 1982;1:53–64.CrossRefPubMedGoogle Scholar
  6. 6.
    Molineux G. The design and development of pegfilgrastim (PEG-rmetHuG-CSF, Neulasta). Curr Pharm Des. 2004;10:1235–44.CrossRefPubMedGoogle Scholar
  7. 7.
    Burgess AW, Camakaris J, Metcalf D. Purification and properties of colony-stimulating factor from mouse lung-conditioned medium. J Biol Chem. 1977;252:1998–2003.PubMedGoogle Scholar
  8. 8.
    Gough NM, Gough J, Metcalf D, et al. Molecular cloning of cDNA encoding a murine haematopoietic growth regulator, granulocyte–macrophage colony stimulating factor. Nature. 1984;309:763–7.CrossRefPubMedGoogle Scholar
  9. 9.
    Bagby G, Heinrich M. Growth factors, cytokines, and the control of hematopoiesis. In: Hoffman R, Shattil SJ, editors. Haematology basic principles and practice. Philadelphia, PA: Churchill Livingstone; 2000. pp. 154–202.Google Scholar
  10. 10.
    Moore M. Colony stimulating factors: basic principles and preclinical studies. In: Rosenberg S, editor. Principles and practice of the biologic therapy of cancer. Philadelphia, PA: Lippincott Williams & Wilkins; 2000. pp. 113–40.Google Scholar
  11. 11.
    Demir G, Klein HO, Tuzuner N. Low dose daily rhGM-CSF application activates monocytes and dendritic cells in vivo. Leuk Res. 2003;27:1105–8.CrossRefPubMedGoogle Scholar
  12. 12.
    Elliott S, Lorenzini T, Asher S, et al. Enhancement of therapeutic protein in vivo activities through glycoengineering. Nat Biotechnol. 2003;21:414–21.CrossRefPubMedGoogle Scholar
  13. 13.
    Allon M, Kleinman K, Walczyk M, et al. Pharmacokinetics and pharmacodynamics of darbepoetin alfa and epoetin in patients undergoing dialysis. Clin Pharmacol Ther. 2002;72:546–55.CrossRefPubMedGoogle Scholar
  14. 14.
    Birgegard G, Wide L, Simonsson B. Marked erythropoietin increase before fall in Hb after treatment with cytostatic drugs suggests mechanism other than anaemia for stimulation. Br J Haematol. 1989;72:462–6.CrossRefPubMedGoogle Scholar
  15. 15.
    Smith DH, Goldwasser E, Vokes EE. Serum immunoerythropoietin levels in patients with cancer receiving cisplatin-based chemotherapy. Cancer. 1991;68:1101–5.CrossRefPubMedGoogle Scholar
  16. 16.
    Schapira L, Antin JH, Ransil BJ, et al. Serum erythropoietin levels in patients receiving intensive chemotherapy and radiotherapy. Blood. 1990;76:2354–9.PubMedGoogle Scholar
  17. 17.
    Auerbach M, Ballard H, Trout JR, et al. Intravenous iron optimizes the response to recombinant human erythropoietin in cancer patients with chemotherapy-related anemia: a multicenter, open-label, randomized trial. J Clin Oncol. 2004;22:1301–7.CrossRefPubMedGoogle Scholar
  18. 18.
    Douglas VK, Tallman MS, Cripe LD, et al. Thrombopoietin administered during induction chemotherapy to patients with acute myeloid leukemia induces transient morphologic changes that may resemble chronic myeloproliferative disorders. Am J Clin Pathol. 2002;117:844–50.CrossRefPubMedGoogle Scholar
  19. 19.
    Vadhan-Raj S. Recombinant human thrombopoietin: clinical experience and in vivo biology. Semin Hematol. 1998;35:261–8.PubMedGoogle Scholar
  20. 20.
    Vadhan-Raj S. Clinical experience with recombinant human thrombopoietin in chemotherapy-induced thrombocytopenia. Semin Hematol. 2000;37:28–34.CrossRefPubMedGoogle Scholar
  21. 21.
    Nurden AT, Viallard JF, Nurden P. New-generation drugs that stimulate platelet production in chronic immune thrombocytopenic purpura. Lancet. 2009;373:1562–9.CrossRefPubMedGoogle Scholar
  22. 22.
    Deutsch VR, Tomer A. Megakaryocyte development and platelet production. Br J Haematol. 2006;134:453–66.CrossRefPubMedGoogle Scholar
  23. 23.
    Gordon MS, McCaskill-Stevens WJ, Battiato LA, et al. A phase I trial of recombinant human interleukin-11 (neumega rhIL-11 growth factor) in women with breast cancer receiving chemotherapy. Blood. 1996;87:3615–24.PubMedGoogle Scholar
  24. 24.
    Isaacs C, Robert NJ, Bailey FA, et al. Randomized placebo-controlled study of recombinant human interleukin-11 to prevent chemotherapy-induced thrombocytopenia in patients with breast cancer receiving dose-intensive cyclophosphamide and doxorubicin. J Clin Oncol. 1997;15:3368–77.PubMedGoogle Scholar
  25. 25.
    Wang B, Nichol JL, Sullivan JT. Pharmacodynamics and pharmacokinetics of AMG 531, a novel thrombopoietin receptor ligand. Clin Pharmacol Ther. 2004;76:628–38.CrossRefPubMedGoogle Scholar
  26. 26.
    Jenkins JM, Williams D, Deng Y, et al. Phase 1 clinical study of eltrombopag, an oral, nonpeptide thrombopoietin receptor agonist. Blood. 2007;109:4739–41.CrossRefPubMedGoogle Scholar
  27. 27.
    Abboud CN, Liesveld JL. Granulopoiesis and monocytopoiesis. In: Hoffman R, et al., editors. Hematology: basic principles and practice. 2nd ed. New York, NY: Churchill Livingstone; 1995. p. 258.Google Scholar

Copyright information

© Springer Science+Business Media, LLC 2010

Authors and Affiliations

  1. 1.Duke University and the Duke Comprehensive Cancer CenterDurhamUSA
  2. 2.Department of MedicineUniversity of WashingtonSeattleUSA

Personalised recommendations